Social health inequalities during the course of chronic HIV disease in the era of highly active antiretroviral therapy

AIDS

Volumn 17, Issue 3, 2003, Pages 283-290

  Dray Spira, Rosemary ^a   Lert, France ^a  

^a INSERM   (France)

Author keywords

Case management; Chronic disease; HIV infection; Industrialized countries; Living condition; Social health inequalities

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ZIDOVUDINE;

CHRONIC DISEASE; COMORBIDITY; EMPLOYMENT; EUROPE; FINANCIAL MANAGEMENT; HEALTH BEHAVIOR; HEALTH SERVICE; HEALTH STATUS; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; LIFESTYLE; MEDICAL CARE; NONHUMAN; OCCUPATION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SOCIAL ASPECT; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; SOCIOECONOMICS; UNITED STATES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH BEHAVIOR; HEALTH SERVICES ACCESSIBILITY; HEALTH STATUS; HIV INFECTIONS; HUMANS; INCOME; INTERPERSONAL RELATIONS; LIFE STYLE; PATIENT COMPLIANCE; SOCIOECONOMIC FACTORS;

EID: 0037436192     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200302140-00001     Document Type: Review

References (107)

1. UNAIDS.AIDS Epidemic Update December 2001. Geneva: UNAIDS; 2000:01.74E.
2. Auvinen A, Karjalainen S, Pukkala E. Social class and cancer patient survival in Finland. Am J Epidemiol 1995, 142:1089-1102.
3. Marcella S, Miller JE. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J Clin Epidemiol 2001, 54:359-366.
4. Vagero D, Persson G. Cancer survival and social class in Sweden. J Epidemiol Community Health 1987, 41:204-209.
5. Koskinen SV, Martelin TP, Valkonen T. Socioeconomic differences in mortality among diabetic people in Finland: five year follow up. BMJ 1996, 313:975-978.
6. Brekke M, Hjortdahl P, Thelle DS, Kvlen TK. Disease activity and severity in patients with rheumatoid arthritis: relations to socio-economic inequality. Soc Sci Med 1999, 48:1743-1750.
7. Escalante A, Del RI. How much disability in rheumatoid arthritis is explained by rheumatoid arthritis? Arthritis Rheum 1999, 42:1712-1721.
8. Fex E, Larsson BM, Nived K, Eberhardt K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 1998, 25:44-50.
9. Koskenvuo M, Kaprio J, Romo M, Langinvainio H. Incidence and prognosis of ischaemic heart disease with respect to marital status and social class. A national record linkage study. J Epidemiol Community Health 1981, 35:192-196.
10. Blank N, Diderichsen F. The prediction of different experiences of long-term illness: a longitudinal approach in Sweden. J Epidemiol Community Health 1996, 50:156-161.
11. Blank N, Diderichsen F. Social inequalities in the experience of illness in Sweden: a 'double suffering'. Scand J Soc Med 1996, 24:81-89.
12. Maynard C, Fisher LD, Passamani ER, Pullum T. Blacks in the coronary artery surgery study (CASS: race and clinical decision making. Am J Public Health 1986, 76:1446-1448.
13. Powe NR, Griffiths RI, de Lissovoy G, Anderson GF, Watson AJ, Greer JW, et al. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 1992, 268:1434-1440.
14. Diehr P, Yergan J, Chu J, Feigl P, Glaefke G, Moe R, et al. Treatment modality and quality differences for black and white breast-cancer patients treated in community hospitals. Med Care 1989, 27:942-958.
15. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989, ii:888-891.
16. Ardron M, MacFarlane I, Robinson C. Educational achievements, employment and social class of insulin-dependent diabetics: a survey of a young adult clinic in Liverpool. Diabet Med 1987, 4:546-548.
17. Gafvels C, Borjesson B, Lithner F. The social consequences of insulin-treated diabetes mellitus in patients 20-50 years of age. An epidemiological case-control study. Scand J Soc Med 1991, 19:86-93.
18. Lloyd CE, Robinson N, Fuller JH. Education and employment experiences in young adults with type 1 diabetes mellitus. Diabet Med 1992, 9:661-666.
19. Albers JM, Kuper HH, van Riel PL, Prevoo ML, 't Hof MA, van Gestel AM, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology 1999, 38:423-430.
20. Eberhardt K, Larsson BM, Nived K. Early rheumatoid arthritis - some social, economical, and psychological aspects. Scand J Rheumatol 1993, 22:119-123.
21. van de Mheen H, Stronks K, Schrijvers CT, Mackenbach JP. The influence of adult ill health on occupational class mobility and mobility out of and into employment in the The Netherlands. Soc Sci Med 1999, 49:509-518.
22. Bartley M, Owen C. Relation between socioeconomic status, employment, and health during economic change, 1973-93. BMJ 1996, 313:445-449.
23. Burstrom B, Whitehead M, Lindholm C, Diderichsen F. Inequality in the social consequences of illness: how well do people with long-term illness fare in the British and Swedish labor markets? Int J Health Serv 2000, 30:435-451.
24. Lindholm C, Burstrom B, Diderichsen F. Class differences in the social consequences of illness? J Epidemiol Community Health 2002, 56:188-192.
25. Fitzpatrick R, Newman S, Archer R, Shipley M. Social support, disability and depression: a longitudinal study of rheumatoid arthritis. Soc Sci Med 1991, 33:605-611.
26. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
27. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
28. Lee M, Rotheram-Borus MJ. Challenges associated with increased survival among parents living with HIV. Am J Public Health 2001, 91:1303-1309.
29. Porta D, Rapiti E, Forastiere F, Pezzotti P, Perucci CA. Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998. Lazio AIDS Surveillance Collaborative Group. AIDS 1999, 13:2125-2131.
30. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001, 15:1115-1123.
31. Rapiti E, Porta D, Forastiere F, Fusco D, Perucci CA. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Lazio AIDS Surveillance Collaborative Group. Epidemiology 2000, 11:496-501.
32. Zingmond DS, Wenger NS, Crystal S, Joyce GF, Liu H, Sambamoorthi U, et al. Circumstances at HIV diagnosis and progression of disease in older HIV-infected Americans. Am J Public Health 2001, 91:1117-1120.
33. Institut de Veille Sanitaire. Surveillance of AIDS cases in France. Situation on Sept 30, 2001. [In French.] Bull Epidemiol Hebdom 2001, 47:207-213.
34. Calvez M. Social Precariousness, Access to HIV Testing and Healthcare: Elements from New AIDS Cases Diagnosed Between 1997 and 2000. [In French.] Rhône Alpes, Villefontaine, France: CRAES/CRIPS, July 2001.
35. Institut de Veille Sanitaire. AIDS in the Foreign Population Living in France. [In French.] Saint-Maurice, France: Institut de Veille Sanitaire; 1999.
36. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 2001, 15:77-85.
37. Kitahata MM, van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. J Acquir immune Defic Syndr 2000, 24:106-114.
38. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. J Am Med Assoc 1998, 280:547-549.
39. Katz MH, Hsu L, Lingo M, Woelffer G, Schwarcz SK. Impact of socioeconomic status on survival with AIDS. Am J Epidemiol 1998, 148:282-291.
40. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med 1994, 331:450-459.
41. Cohn SE, Berk ML, Berry SH, Duan N, Frankel MR, Klein JD, et al. The care of HIV-infected adults in rural areas of the United States. J Acquir Immune Defic Syndr 2001, 28:385-392.
42. Chauvin P, Mortier E, Carrat F, Imbert JC, Valleron AJ, Lebas J. A new out-patient care facility for HIV-infected destitute populations in Paris, France. AIDS Care 1997, 9:451-459.
43. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. J Am Med Assoc 1999, 281:2305-2315.
44. Lert F, Obadia Y, Dray-Spira R, Marimoutou C, Bouhnik AD. Study of the Social Situation of Persons Living with HIV/AIDS and the Responsiveness of the Healthcare System and Social Services. [In French.] Paris, France: INSERM U88-ORS PACA/INSERM U379; December 2001.
45. Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res 1995, 30:593-614.
46. Cook JA, Cohen MH, Grey D, Kirstein L, Burke J, Anastos K, et al. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health 2002, 92:82-87.
47. Hsu LC, Vittinghoff E, Katz MH, Schwarcz SK. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J Acquir Immune Defic Syndr 2001, 28:345-350.
48. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999, 13:2547-2554.
49. Keruly JC, Conviser R, Moore RD. Association of medical insurance and other factors with receipt of antiretroviral therapy. Am J Public Health 2002, 92:852-857.
50. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999, 22:369-378.
51. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000, 24:475-482.
52. Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000, 14:1829-1837.
53. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. J Am Med Assoc 1998, 280:544-546.
54. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health 1999, 53:4-8.
55. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001, 27:251-259.
56. Rompalo AM, Shah N, Mayer K, Schuman P, Klein RS, Smith DK, et al. Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV epidemiology research study: on-site versus referral care. J Acquir Immune Defic Syndr 2001, 28:28-34.
57. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV- infected injection drug users. AIDS 2001, 15:1707-1715.
58. Michaels SH, Clark R, Kissinger P. Use of antiretroviral therapy by intravenous drug users with HIV. J Am Med Assoc 1999, 281:699-700.
59. Turner BJ, Fleishman JA, Wenger N, London AS, Burnam MA, Shapiro MF, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med 2001, 16:625-633.
60. Chauvin P, de Montaigne AB, Lebas J. Précarités, maladie et soins médicaux. Méd Mal Infect 2000, 30(Suppl 3):205-214.
61. Cinti SK. Adherence to antiretrovirals in HIV disease. AIDS Read 2000, 10:709-717.
62. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, de Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001, 28:445-449.
63. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000, 19:124-133.
64. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000, 30(Suppl 2):S171-S176.
65. Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care 2000, 12:377-386.
66. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002, 16:767-774.
67. Sherer R. Adherence and antiretroviral therapy in injection drug users. J Am Med Assoc 1998, 280:567-568.
68. Gebo KA, Keruly JC, Moore RD. Is illicit drug use a risk factor for non-adherence to antiretroviral therapy? Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001.
69. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, et al. Failure to maintain long-term adherence to highly active anti-retroviral therapy: the role of lipodystrophy. AIDS 2001, 15:2441-2444.
70. Moatti J, Spire B, Duran S. A review of socio-behavioural studies on adherence to antiretroviral treatments: beyond biomedical models? [In French.] Rev Epidemiol Sante Publ 2000, 48:182-198.
71. Di Martino V, Ezenfis J, Tainturier MH, Benhamou Y, Bochet M, Katlama C, et al. Impact of HIV coinfection on the longterm outcome of HCV cirrhosis. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001.
72. Lesens O, Deschênes M, Steben M, Bélanger G, Tsoukas C. Hepatitis C virus is related to progressive liver disease in HIV-positive haemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999, 179:1254-8.
73. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002, 16:813-828.
74. Sulkowski M, Mast E, Seeff L, Thomas D. Hepatitis C virus infection as an opportunistic disease in persons infected with HIV. Clin Infect Dis 2000, 30(Suppl 1):77-84.
75. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492-497.
76. Di Pierri G, Raiteri R, Bonora S, Sciandra M, Marcati P, Allegranzi B, et al. Liver failure from HCV as the current leading cause of death in HIV-infected patients in Northern Italy. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001.
77. Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001, 17:1467-1471.
78. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus- infected adults in the United States. Arch Gen Psychiatry 2001, 58:721-728.
79. Mientjes GH, van Ameijden EJ, van den Hoek AJ, Coutinho RA. Increasing morbidity without rise in non-AIDS mortality among HIV- infected intravenous drug users in Amsterdam. AIDS 1992, 6:207-212.
80. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med 1994, 331:450-459.
81. Selwyn PA, Feingold AR, Hartel D, Schoenbaum EE, Alderman MH, Klein RS, et al. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988, 2:267-272.
82. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. J Am Med Assoc 2001, 285:1466-1474.
83. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001, 28:351-357.
84. Roth MD, Tashkin DP, Choi R, Jamieson BD, Zack JA, Baldwin GC. Cocaine enhances HIV replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis 2002, 185:701-705.
85. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 2001, 15:1295-1302.
86. van Deutekom H, Gerritsen JJ, van Soolingen D, van Ameijden EJ, van Embden JD, Coutinho RA. A molecular epidemiological approach to studying the transmission of tuberculosis in Amsterdam. Clin Infect Dis 1997, 25:1071-1077.
87. Chin DP, DeRiemer K, Small PM, de Leon AP, Steinhart R, Schecter GF, et al. Differences in contributing factors to tuberculosis incidence in US-born and foreign-born persons. Am J Respir Crit Care Med 1998, 158:1797-1803.
88. Hammarstrom A, Janlert U. Early unemployment can contribute to adult health problems: results from a longitudinal study of school leavers. J Epidemiol Community Health 2002, 56:624-630.
89. Gutierrez MC, Vincent V, Aubert D, Bizet J, Gaillot O, Lebrun L, et al. Molecular fingerprinting of Mycobacterium tuberculosis and risk factors for tuberculosis transmission in Paris, France, and surrounding area. J Clin Microbiol 1998, 36:486-492.
90. Barnes PF, el Hajj H, Preston-Martin S, Cave MD, Jones BE, Otaya M, et al. Transmission of tuberculosis among the urban homeless. J Am Med Assoc 1996, 275:305-307.
91. Centers for Disease Control and Prevention. Tuberculosis outbreaks in prison housing units for HIV-infected inmates- -California, 1995-1996. MMWR 1999, 48:79-82.
92. Chaves F, Dronda F, Alonso-Sanz M, Noriega AR. Evidence of exogenous reinfection and mixed infection with more than one strain of Mycobacterium tuberculosis among Spanish HIV- infected inmates. AIDS 1999, 13:615-620.
93. Gharakhanian S. The HIV-associated lipodystrophy syndrome: research, results, yet more questions. AIDS 2001, 15:271-273.
94. Kadushin G. Barriers to social support and support received from their families of origin among gay men with HIV/AIDS. Health Soc Work 1999, 24:198-209.
95. Swindells S, Mohr J, Justis JC, Berman S, Squier C, Wagener MM, et al. Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness. Int J STD AIDS 1999, 10:383-391.
96. Cunningham WE, Andersen RM, Katz MH, Stein MD, Turner BJ, Crystal S, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with Human Immunodeficiency Virus receiving care in the United States. Med Care 1999, 37:1270-1281.
97. Fleishman JA. Transitions in insurance and employment among people with HIV infection. Inquiry 1998, 35:36-48.
98. Association AIDES. Study of Attendees of AIDES Association: Synthesis of the Results. [In French.] Paris, France: Association AIDES; 1999.
99. Fabre G, Tchobanian R. Current tensions between HIV and employment. [In French.] Sc Soc Santé 2001, 19:43-67.
100. Ezzy D, De Visser R, Grubb I, McConachy D. Employment, accommodation, finances and combination therapy: the social consequences of living with HIV/AIDS in Australia. AIDS Care 1998, 10(Suppl 2):S189-S199.
101. Ezzy D, De Visser R, Bartos M. Poverty, disease progression and employment among people living with HIV/AIDS in Australia. AIDS Care 1999, 11:405-414.
102. Yelin EH, Greenblatt RM, Hollander H, McMaster JR. The impact of HIV-related illness on employment. Am J Public Health 1991, 81:79-84.
103. Virtanen P, Vahtera J, Kivimaki M, Pentti J, Ferrie J. Employment security and health. J Epidemiol Community Health 2002, 56:569-574.
104. Brooks RA, Klosinski LE. Assisting persons living with HIV/AIDS to return to work: programmatic steps for AIDS service organizations. AIDS Educ Prev 1999, 11:212-223.
105. Voelker R. Protease inhibitors bring new social, clinical uncertainties to HIV care. J Am Med Assoc 1997, 277:1182-1184.
106. Bury M. Chronic illness as a biographical discruption. Social Health Illness 1982, 4:167-182.
107. Corbin J, Strauss A. Accompaniments of chronic illness: changes in body, self, biography and biographical time. Res Sociol Health Care 1987, 6:249-281.